Phase I Results of Gunagratinib (ICP-192), a Highly Selective Irreversible FGFR 1-4 Inhibitor in Patients with Head and Neck Cancer Harboring FGF/FGFR Gene Aberrations.

Ye Guo,Qun Li,Wenbo Tang,Fengjuan Lin,Junli Xue,Liqiong Xue,Xiaoxiao Ge,Wei Zhao,Wei Zhou,Renbin Zhao,Bin Zhang,Jin Li

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.6039

IF: 45.3

2022-01-01

Journal of Clinical Oncology

Abstract:6039 Background: The fibroblast growth factor (FGF) and FGF receptor (FGFR) signaling pathway has been evaluated as critical driver of carcinogenesis in multiple cancer types. However, primary results of several FGFR inhibitors showed no or limited response in head and neck cancer (HNC) with FGF/FGFR gene aberrations. Here, we evaluated the efficacy and safety of a novel irreversible pan-FGFR inhibitor gunagratinib in HNC in a first-in-human, phase I/IIa, dose escalation and dose expansion study (ICP-CL-00301 NCT03758664). Methods: In the dose-escalation stage of ICP-CL-00301 study, patients with advanced solid tumors (including HNC) with or without FGF/FGFR gene alterations were treated with escalating doses (range: 2mg-26mg) of gunagratinib once daily in 21-day cycles until disease progression or unacceptable toxicity. Results: 12 HNC patients with or without FGF/FGFR aberrations, including FGF amplification and FGFR mutation, were treated with escalating doses (range: 14mg-22mg) of gunagratinib. Among them, 9 patients harbored FGF/FGFR gene alterations with at least one tumor assessment. The median age of the 12 treated HNC patients was 56 (range: 44 to 75 years) with 75% male and ECOG performance status 1. Among the 9 HNC patients with FGF/FGFR gene aberrations who have completed at least one tumor assessment, 3 patients had partial response (PR), the overall response rate (ORR) was 33.3% (3 of 9 patients). The disease control rate (DCR) was 66.7% (6 of 9 patients). Total of 62 patients with solid tumor were enrolled in ICP-CL-00301 study. The most common treatment-related adverse events (TRAEs) (≥15%) included hyperphosphatemia, diarrhea, increased ALT or AST, increased alkaline phosphatase, hypercalcemia, increased serum creatinine, dry mouth, hypertriglyceridemia, anemia and hyperuricemia. In ICP-CL-00301 study, 3 serious TRAEs were reported, and no serious TRAE were reported in HNC patients. Conclusions: This study demonstrated the anti-tumor activity of gunagratinib in HNC patients carrying FGF/FGFR gene aberrations with an ORR of 33.3%. Gunagratinib is safe and well-tolerated in patients with advanced solid tumors including HNC. Clinical trial information: NCT03758664. Tumor histological type and gene alteration type. Histological Type N=12 [1] squamous cell cancer 8 Ameloblastic carcinoma 2 Nasopharyngeal carcinoma 3 Gene alterations Type N=10 [2] FGF 7 FGFR 3 [1] One patient was a nasopharyngeal carcinoma patient with tongue squamous cell cancer. [2] One patient had no imaging tumor evaluation.